medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2009, Number 6

<< Back Next >>

Rev Mex Oftalmol 2009; 83 (6)

Resultados de la aplicación de mitomicina-C transoperatoria versus postoperatoria en cirugía de pterigión

Villarreal MAL, Noriega AA, Rodríguez GA

Language: Spanish
References: 28
Page: 385-389
PDF size: 93.30 Kb.


ABSTRACT

Purpose: To evaluate and compare the efficacy of intra-operative versus post-operative mitomycin-C (MMC) in the recurrence rate of primary pterygium, as well as the safety of such treatment modalities.
Methods: In a case-control study, a total of 120 eyes of 114 patients homologous for demographics and surgical procedure for primary pterygium were evaluated. The eyes were divided into two groups: those who received intra-operative MMC in a concentration of 0.04% (group A) and those who received post-operative MMC in a concentration of 0.04% in the form of topical eye drops three times a day for 2 weeks (group B). The presence of recurrence and/or MMC associated complications were evaluated in a minimum of 2 months (range: 2 weeks–9 months).
Results: A total of 34 pterygia were included in group A and 86 were included in group B. Although a lower recurrence rate was observed after 2 months in group A (8.8%) when compared to group B (17.4%) statistical analysis showed no significant difference (pe»0.364). There were no complications in group A, while 2 were reported in group B: corneoscleral thinning and corneal Dellen.
Conclusions: Data from our study suggest that both application forms of MMC share similar efficacy in the rate of recurrence prevention after primary pterygium surgery and that both treatment modalities are safe.


REFERENCES

  1. Hoffman RS, Power WJ. Current options in pterygium management. Int Ophthalmol Clin 1999; 39:15-26.

  2. Mackenzie FD, Hirst LW, Battistuta D, Green A. Risk analysis in the development of pterygia. Ophthalmology 1992; 99:1056-1061.

  3. Sutphin JE, Dana MR, Florakis GJ y cols. Degenerative and Aging Processes of the Conjunctiva, Cornea, and Sclera. En: External Disease and Cornea: Basic and Clinical Course. Section 8. San Francisco, CA: AAO; 2008-2009:366.

  4. Allan BD, Short P, Crawford GJ y cols. Pterygium excision with conjunctival autografting: an effective and safe technique. Br J Ophthalmol 1993; 77:698-701.

  5. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol 1984; 68:343-346.

  6. Ang LPK, Chua JLL, Tan DTH. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 2007; 18:308-313.

  7. Tseng SCG, Chen JJY, Huang AJW y cols. Classification of conjunctival surgeries for corneal diseases based on stem cell concept. Ophthamol Clin North Am 1990; 3:595-610.

  8. Coroneo MT, DiGirolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 1999; 10:282-288.

  9. D’Ombrain A. The surgical treatment of pterygium. Br J Ophthalmol 1948; 32:65.

  10. Kammoun B, Kharrat W, Zovari K y cols. Pterygium: surgical treatment. J Fr Ophthalmol 2001; 24 :823-828.

  11. Singh G, Wilson MR, Foster CS. Mitomycin eye drops as treatment for pterygium. Ophthalmology 1988; 95:813-821.

  12. Kunitomo N, Mori S. Studies on pterygium: report IV. A treatment pterygium by mitomycin-C. Acta Soc Ophthalmol Jpn 1963; 67:601-607.

  13. Raiksup F, Solomon A, Landau D, Ilsar M, Frucht-Pery J. Mitomycin C for pterygium: long term evaluation. Br J Ophthalmol 2004; 88:1425-1428.

  14. Buratto L, Phillips RL, Carito G. Pterygium Surgery. Thorofare, NJ: Slack Incorporated, 2000.

  15. Nakamura M, Yamamoto M. DNA interstrand crosslinking agents and human ocular fibroblasts: differential sensitivity to mitomycin C and cisdiamodichloroplatinum. Exp Eye Res 1994; 59:53-62.

  16. Frucht-Pery J, Siganos CS, Ilsar M. Intraoperative application of topical mitomycin C for pterygium surgery. Ophthalmology 1996; 103:674-677.

  17. Donnefeld ED, Perry RD, Fromer S y cols. Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology 2003; 110:1012-1016.

  18. Rachmiel R, Leiba H, Levartovsky S. Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium. Br J Ophthalmol 1995; 79:233-236.

  19. Rubinfeld RS, Pfester RR, Stein RM y cols. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 1992; 99:1647-1654.

  20. Hayasaka S, Noda S, Yamamoto Y y cols. Postoperative instillation of mitomycin C in the recurrent pterygium. Ophthalmic Surg 1989; 20:580-583.

  21. Rubinfeld RS, Stein RM. Topical mitomycin C for pterygia: is a single application appropriate? Opthalmic Surg Lasers 1997; 28:662-669.

  22. DSC, Wong AKK, Fan DSP y cols. Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. Ophthalmology 1998; 105:901-905.

  23. Cardillo JA, Alves MR, Ambrosio LE y cols. Single intra-operative application versus postoperative mitomycin C Eye Drops in Pterygium Surgery. Ophthalmology 1995; 102:1949-1952.

  24. Pflugfelder SC, Beuerman RW, Stern ME. Sex and Sex Steroid Influences on Dry Eye Syndrome. En: Dry Eye and Ocular Surface Disorders. New York, NY: Marcel Dekker, Inc., 2004.

  25. Chen HC, Tseng SH, Kao PL y cols. Low-dose Intraoperative Mitomycin C as Chemoadjuvant for Pterygium Surgery. Cornea 2001; 20(1):24-29.

  26. Avisar R, Gaton D, Loya N y cols. Intraoperative Mitomycin C 0.02% for Pterygium. Cornea 2003; 22(2):102-104.

  27. Panda A, Das GK, Tuli SW y cols. Randomized Trial of Intraoperative Mitomycin C in Surgery for Pterygium. Am J Ophthalmol 1998; 125:59-63.

  28. Hirst LW, Sebban A, Chant D. Pterygium Recurence Time. Ophthalmology 1994; 101:755-758.




2020     |     www.medigraphic.com